Abnormal accumulation of tau is seen across various central nervous system disorders such as AD, Pick’s disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease; thus, targeting tau offers the possibility not only of treating AD itself but also of treating many other tauopathies associated with Aβ. This evidence concerns the gene MAPT and progressive supranuclear palsy.